Overview
Spain has no peptide-specific statute; peptides are handled under general EU/Spanish medicines law, which means any product presented for human therapeutic use must hold a marketing authorisation from the AEMPS or the EU before it can be sold or supplied. Approved peptide medicines such as semaglutide, liraglutide, tirzepatide and somatropin are prescription-only and dispensed through licensed pharmacies, while unapproved 'research' peptides such as BPC-157, TB-500 or CJC-1295 have no authorisation and cannot lawfully be marketed for human use. Spanish and EU regulators have issued explicit warnings about illegal online GLP-1 products, and online sale to the public is limited by law to non-prescription medicines from registered pharmacy websites. Several growth-hormone-related peptides are additionally banned in sport, and supplying them to athletes can trigger criminal liability.
Key Points
- Spain regulates peptides through its general medicines framework — the consolidated Law of guarantees and rational use of medicines and health products (Real Decreto Legislativo 1/2015) — which governs authorisation, registration and dispensing conditions for human medicines, rather than through any peptide-specific statute. [1]
- The AEMPS, together with EMA and the Heads of Medicines Agencies, has warned about a sharp increase in illegal medicines marketed as GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) sold through fraudulent websites and promoted on social media, which are unauthorised and do not meet quality, safety and efficacy standards. [2]
- Products marketed without authorisation while claiming therapeutic properties are treated by the AEMPS as illegal medicines, and the agency can order their market withdrawal, quarantine or prohibition of commercialisation. [3]
- Distance selling to the public in Spain is legally limited to industrially manufactured medicines NOT subject to medical prescription, sold only through the websites of legally authorised community pharmacies, so online consumer sale of prescription-strength peptide drugs falls outside the lawful channel. [4]
- The AEMPS runs an active campaign against illegal online sale of medicines, noting that such channels supply products without the medical control required for substances that need a prescription. [5]
- Physical importation of medicines into Spain is a licensed activity: after customs clearance the medicine must be sent to the premises of a pharmaceutical laboratory authorised for importation under Real Decreto 824/2010, meaning there is no general commercial import route for individuals or non-licensed sellers. [6]
- Growth-hormone-releasing peptides (GHRP-1, GHRP-2/pralmorelin, GHRP-4, GHRP-5, GHRP-6, hexarelin, alexamorelin) and growth factors are expressly listed in category S2 of Spain's official prohibited substances and methods list for sport, approved by Resolution of 2 December 2025 of the Presidency of the Consejo Superior de Deportes and published in the BOE. [7]
- Prescribing, providing or supplying prohibited performance-enhancing substances to athletes is criminalised in Spain as a public-health offence under Article 362 quinquies of the Criminal Code. [8]
- No primary Spanish source was located confirming whether BPC-157, TB-500 or similar 'research' peptides appear on (or are absent from) Spain's narcotics/psychotropics schedules; the restrictions described above derive from medicines and anti-doping law rather than from confirmed drug scheduling, and the 'not for human consumption' research-chemical trade remains a practical enforcement gray zone. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)